FMTX Profile
Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapies for patients with rare hematologic diseases and cancers. The company has a diverse pipeline of potential therapies, which target various cellular pathways involved in disease progression. FMTX's technology platform includes a proprietary drug discovery engine that combines insights from biology and chemistry to develop targeted therapies with optimized pharmacological properties.
FMTX's lead drug candidate, FT-4202, is currently in Phase 3 clinical trials for sickle cell disease. The company also has multiple other drug candidates in clinical and pre-clinical development for various indications.
While FMTX has reported losses in recent periods as it invests in research and development activities, the company has a strong balance sheet with significant cash reserves. As of September 30, 2021, the company had total assets of $722.4 million and cash, cash equivalents, and marketable securities of $671.4 million. FMTX believes that its cash reserves will be sufficient to fund its operations into 2024.
Overall, FMTX is a clinical-stage biopharmaceutical company with a diverse pipeline of potential therapies for rare hematologic diseases and cancers. The company has a strong balance sheet and is well-positioned to continue its research and development activities.
|
